Shopping Cart
Remove All
Your shopping cart is currently empty
Ulenistamab
(Synonyms: PBP1510, PBP 1510) Copy Product Info
🥰Excellent
Synonyms: PBP1510, PBP 1510
Catalog No. T78306 Copy Product Info
Purity: 95%
🥰Excellent
Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody that specifically targets pancreatic adenocarcinoma upregulated factor (PAUF), Ulenistamab is extensively used in pancreatic cancer research to investigate PAUF-driven tumor progression, tumor microenvironment modulation, and antibody-based therapeutic strategies for pancreatic adenocarcinoma.
Cas No. 2415259-90-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | - | In Stock | |
| 5 mg | $753 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.4% (SDS-PAGE); 99.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ulenistamab (PBP1510) is a first-in-class humanised IgG1 monoclonal antibody that specifically targets pancreatic adenocarcinoma upregulated factor (PAUF), Ulenistamab is extensively used in pancreatic cancer research to investigate PAUF-driven tumor progression, tumor microenvironment modulation, and antibody-based therapeutic strategies for pancreatic adenocarcinoma. |
| In vitro | In preclinical studies using human pancreatic cancer (PC) cell lines CFPAC-1 and BxPC-3, Ulenistamab treatment inhibited cell proliferation. The antibody reduced the metastatic potential of these cells by suppressing their migration and invasion capabilities [1]. |
| In vivo | The pharmacokinetic (PK) profiles and immunogenicity of Ulenistamab (PBP1510) (up to 20 mg/kg) were examined in a single-dose study involving 6 monkeys. Systemic exposure in the monkey study was observed to increase in a dose-proportional manner at both low and high doses [1]. |
| Synonyms | PBP1510, PBP 1510 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | PAUF |
| Molecular Weight | 147.63 kDa |
| Cas No. | 2415259-90-2 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: Ulenistamab chemical structure | Ulenistamab in vivo | Ulenistamab in vitro | Ulenistamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.